Ajinomoto Announces the Approval of the 32nd Drug Product at their San Diego
Ajinomoto Bio-Pharma Services Garners Six 'CDMO Leadership Awards
New acquisition to support global gene therapy manufacturing
Ajinomoto Bio Pharma Services, a global provider of biopharmaceutical contract development and manufacturing services, appointed Bert Barbosa, president and chief operating officer, U.S.
March 14, 2023 – (San Diego, CA, Tokyo, Japan and Wetteren, Belgium) – Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading provider of biopharmaceutical contract development and manufacturing services, received three CDMO Leadership Awards in the categories Capabilities, Compatibility, and Expertise in both the Overall and Big Pharma respondent groups.
Until this year, there were no treatments for transthyretin amyloidosis, a rare disease where misfolding transthyretin (TTR) proteins build up in the body’s tissues. Then, in quick succession, the FDA approved a pair of drugs that interfere with RNA to block the production of these proteins. Another drug in the pipeline works similarly, by stabilizing TTR and stopping it from folding incorrectly.